Ron Gibson, MD, PhD

Ron Gibson, MD, PhD

Pulmonary, Cystic Fibrosis Research, Cystic Fibrosis Program

On staff since November 1987

Children's Title: Director, Cystic Fibrosis Center; Co-Director, Cystic Fibrosis Therapeutic Development Center; Associate Program Director, Pediatric Pulmonary Fellowship

Academic Title: Professor

Research Center: Center for Respiratory Biology and Therapeutics

  • Biography

    Ronald L. Gibson, MD, PhD, is Director of the Cystic Fibrosis (CF) Center, Director of the Pediatric Pulmonary Fellowship program, and attending physician at Seattle Children’s Hospital; he is a Professor in the Department of Pediatrics at the University of Washington School of Medicine. He earned his MD and PhD at Washington University in St. Louis. He completed pediatrics residency training and a fellowship in pediatric pulmonology at the University of Washington.

    He is committed to high-quality, multidisciplinary patient care, small group teaching, research and the acquisition of new knowledge. His primary research focus is on early events in the pathogenesis of lung disease in CF, with a focus on the risk factors for and the treatment of Pseudomonas aeruginosa airway infections in young children with cystic fibrosis (CF). As a co–principal investigator of the university’s CF Translational Therapeutic Development Center, he has been lead and co-investigator for several phase I to phase III clinical trials involving novel antimicrobial agents, anti-inflammatory compounds and modulators of ion transport. Dr. Gibson is also director of the clinical core of the university’s CF research development program with the goal of catalyzing collaborations between local basic and clinical investigators.

  • Patient Testimonials

    Be the first to recommend Ron Gibson, MD, PhD

  • Awards and Honors

    Award Name Award Description Awarded By Award Date
    SEATTLE TOP DOCTOR - 2022 Seattle Magazine 2022
    Seattle Top Doctor - 2019 Seattle Magazine 2019
    SEATTLE'S TOP DOCTOR - 2018 Seattle Magazine 2018
    SEATTLE'S TOP DOCTOR - 2017 Seattle Magazine 2017
    SEATTLE'S TOP DOCTOR - 2016 Seattle Magazine 2016
    Seattles Top Doctor 2016 Seattle Met Magazine 2016
    SEATTLE'S TOP DOCTOR - 2015 Seattle Met Magazine 2015
    SEATTLE MAGAZINE TOP DOCTOR - 2015 Seattle Magazine 2015
    SEATTLE MAGAZINE TOP DOCTOR - 2014 Seattle Magazine 2014
    SEATTLE'S TOP DOCTOR - 2014 Seattle Metropolitan Magazine 2014
    Seattle's Top Doc Seattle Met Magazine 2013
    Seattle Magazine Top Doctor - 2013 Seattle Magazine 2013
    U.S. News Top Doctor U.S. News and World Report 2012
    Seattle Magazine Top Doctor - 2012 Seattle Magazine Top Doctor - 2012 Seattle Magazine 2012
    Seattles Top Doctors Seattle Magazine 2011
    Seattles Top Doctors Seattle Magazine 2010
    Nominee, Family Choice Award from Family Advisory Council Seattle Children's Hospital 2009
    Mentoring Award from the University of Washington School of Medicine Department of Pediatrics , University of Washington 2008
    Selected to Best Doctors in America Best Doctors in America 2007 - 2009

  • Publications

    Manuscripts in Refereed Journals

    • Mayer-Hamblett N, Rosenfeld M, Gibson RL, Ramsey BW, Kulasekara HD, Retsch-Bogart GZ, Morgan W, Wolter DJ, Pope CE, Houston LS, Kulasekara BR, Khan U, Burns JL, Miller SI, Hoffman LR
      Pseudomonas aeruginosa in vitro Phenotypes Distinguish Cystic Fibrosis Infection Stages and Outcomes.
      24937177 American journal of respiratory and critical care medicine, 2014 June

    Published Abstracts

    • Ron Gibson, MD, PhD
      Abstracts - Available upon request

    Other Publications

    • Zemanick ET, Emerson J, Thompson V, McNamara S, Morgan W, Gibson RL, Rosenfeld M, EPIC Study Group
      Clinical outcomes after initial pseudomonas acquisition in cystic fibrosis.
      24644274 Pediatric pulmonology, 2015 Jan. : 50(1)42-8
    • Brown PS, Pope CE, Marsh RL, Qin X, McNamara S, Gibson R, Burns JL, Deutsch G, Hoffman LR
      Directly sampling the lung of a young child with cystic fibrosis reveals diverse microbiota.
      25072206 Annals of the American Thoracic Society, 2014 Sept. : 11(7)1049-55 PMCID:PMC4214062
    • Emerson J, Cochrane E, McNamara S, Kuypers J, Gibson RL, Campbell AP
      Home Self-Collection of Nasal Swabs for Diagnosis of Acute Respiratory Virus Infections in Children With Cystic Fibrosis.
      24363931 Journal of the Pediatric Infectious Diseases Society, 2013 Dec. : 2(4)345-351 PMCID:PMC3869469
    • Mayer-Hamblett N, Rosenfeld M, Treggiari MM, Konstan MW, Retsch-Bogart G, Morgan W, Wagener J, Gibson RL, Khan U, Emerson J, Thompson V, Elkin EP, Ramsey BW, EPIC, ESCF Investigators
      Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa in cystic fibrosis.
      23818295 Pediatric pulmonology, 2013 Oct. : 48(10)943-53
    • Mayer-Hamblett N, Rosenfeld M, Treggiari MM, Konstan MW, Retsch-Bogart G, Morgan W, Wagener J, Gibson RL, Khan U, Emerson J, Thompson V, Elkin EP, Ramsey BW, EPIC, ESCF Investigators
      Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa in cystic fibrosis.
      23818295 Pediatric pulmonology, 2013 Oct. : 48(10)943-53
    • Guo DC, Regalado E, Casteel DE, Santos-Cortez RL, Gong L, Kim JJ, Dyack S, Horne SG, Chang G, Jondeau G, Boileau C, Coselli JS, Li Z, Leal SM, Shendure J, Rieder MJ, Bamshad MJ, Nickerson DA, GenTAC Registry Consortium, National Heart, Lung, and Blood Institute Grand Opportunity Exome Sequencing Project, Kim C, Milewicz DM
      Recurrent gain-of-function mutation in PRKG1 causes thoracic aortic aneurysms and acute aortic dissections.
      23910461 American journal of human genetics, 2013 Aug 8 : 93(2)398-404 PMCID:PMC3738837
    • Wolter DJ, Emerson JC, McNamara S, Buccat AM, Qin X, Cochrane E, Houston LS, Rogers GB, Marsh P, Prehar K, Pope CE, Blackledge M, Déziel E, Bruce KD, Ramsey BW, Gibson RL, Burns JL, Hoffman LR
      Staphylococcus aureus small-colony variants are independently associated with worse lung disease in children with cystic fibrosis.
      23625938 Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2013 Aug. : 57(3)384-91
    • Fu W, O'Connor TD, Jun G, Kang HM, Abecasis G, Leal SM, Gabriel S, Rieder MJ, Altshuler D, Shendure J, Nickerson DA, Bamshad MJ, NHLBI Exome Sequencing Project, Akey JM
      Analysis of 6,515 exomes reveals the recent origin of most human protein-coding variants.
      23201682 Nature, 2013 Jan 10 : 493(7431)216-20 PMCID:PMC3676746
    • O'Connor TD, Kiezun A, Bamshad M, Rich SS, Smith JD, Turner E, NHLBIGO Exome Sequencing Project, ESP Population Genetics, Statistical Analysis Working Group, Leal SM, Akey JM
      Fine-scale patterns of population stratification confound rare variant association tests.
      23861739 PloS one, 2013 : 8(7)e65834 PMCID:PMC3701690
    • Rosenfeld M, Bernardo-Ocampo C, Emerson J, Genatossio A, Burns J, Gibson R
      Prevalence of cystic fibrosis pathogens in the oropharynx of healthy children and implications for cystic fibrosis care.
      22551927 Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2012 Sept. : 11(5)456-7
    • Rosenfeld M, Emerson J, McNamara S, Thompson V, Ramsey BW, Morgan W, Gibson RL, EPIC Study Group
      Risk factors for age at initial Pseudomonas acquisition in the cystic fibrosis epic observational cohort.
      22554417 Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2012 Sept. : 11(5)446-53
    • Emond MJ, Louie T, Emerson J, Zhao W, Mathias RA, Knowles MR, Wright FA, Rieder MJ, Tabor HK, Nickerson DA, Barnes KC, National Heart, Lung, and Blood Institute (NHLBI) GO Exome Sequencing Project, Lung GO, Gibson RL, Bamshad MJ
      Exome sequencing of extreme phenotypes identifies DCTN4 as a modifier of chronic Pseudomonas aeruginosa infection in cystic fibrosis.
      22772370 Nature genetics, 2012 Jul 8 : 44(8)886-9 PMCID:PMC3702264
    • Quon BS, Patrick DL, Edwards TC, Aitken ML, Gibson RL, Genatossio A, McNamara S, Goss CH
      Feasibility of using pedometers to measure daily step counts in cystic fibrosis and an assessment of its responsiveness to changes in health state.
      22226414 Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2012 May : 11(3)216-22
    • Mayer-Hamblett N, Kronmal RA, Gibson RL, Rosenfeld M, Retsch-Bogart G, Treggiari MM, Burns JL, Khan U, Ramsey BW, EPIC Investigators
      Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis.
      21830317 Pediatric pulmonology, 2012 Feb. : 47(2)125-34 PMCID:PMC3214247
    • Mayer-Hamblett N, Kronmal RA, Gibson RL, Rosenfeld M, Retsch-Bogart G, Treggiari MM, Burns JL, Khan U, Ramsey BW, EPIC Investigators
      Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis.
      21830317 Pediatric pulmonology, 2012 Feb. : 47(2)125-34 PMCID:PMC3214247
    • Oermann CM, McCoy KS, Retsch-Bogart GZ, Gibson RL, McKevitt M, Montgomery AB
      Pseudomonas aeruginosa antibiotic susceptibility during long-term use of aztreonam for inhalation solution (AZLI).
      21784781 The Journal of antimicrobial chemotherapy, 2011 Oct. : 66(10)2398-404
    • Treggiari MM, Retsch-Bogart G, Mayer-Hamblett N, Khan U, Kulich M, Kronmal R, Williams J, Hiatt P, Gibson RL, Spencer T, Orenstein D, Chatfield BA, Froh DK, Burns JL, Rosenfeld M, Ramsey BW, Early Pseudomonas Infection Control (EPIC) Investigators
      Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis.
      21893650 Archives of pediatrics & adolescent medicine, 2011 Sept. : 165(9)847-56
    • Wainwright CE, Quittner AL, Geller DE, Nakamura C, Wooldridge JL, Gibson RL, Lewis S, Montgomery AB
      Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa.
      21441078 Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2011 July : 10(4)234-42
    • Moskowitz SM, Emerson JC, McNamara S, Shell RD, Orenstein DM, Rosenbluth D, Katz MF, Ahrens R, Hornick D, Joseph PM, Gibson RL, Aitken ML, Benton WW, Burns JL
      Randomized trial of biofilm testing to select antibiotics for cystic fibrosis airway infection.
      20963843 Pediatric pulmonology, 2011 Feb. : 46(2)184-92 PMCID:PMC3479399
    • Oermann CM, Retsch-Bogart GZ, Quittner AL, Gibson RL, McCoy KS, Montgomery AB, Cooper PJ
      An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis.
      20672296 Pediatric pulmonology, 2010 Nov. : 45(11)1121-34 PMCID:PMC3867945
    • Rosenfeld M, Emerson J, McNamara S, Joubran K, Retsch-Bogart G, Graff GR, Gutierrez HH, Kanga JF, Lahiri T, Noyes B, Ramsey B, Ren CL, Schechter M, Morgan W, Gibson RL, EPIC Study Group Participating Clinical Sites
      Baseline characteristics and factors associated with nutritional and pulmonary status at enrollment in the cystic fibrosis EPIC observational cohort.
      20597081 Pediatric pulmonology, 2010 Sept. : 45(9)934-44
    • Sanders DB, Hoffman LR, Emerson J, Gibson RL, Rosenfeld M, Redding GJ, Goss CH
      Return of FEV1 after pulmonary exacerbation in children with cystic fibrosis.
      20054859 Pediatric pulmonology, 2010 Feb. : 45(2)127-34
    • Bartlett JR, Friedman KJ, Ling SC, Pace RG, Bell SC, Bourke B, Castaldo G, Castellani C, Cipolli M, Colombo C, Colombo JL, Debray D, Fernandez A, Lacaille F, Macek M Jr, Rowland M, Salvatore F, Taylor CJ, Wainwright C, Wilschanski M, Zemková D, Hannah WB, Phillips MJ, Corey M, Zielenski J, Dorfman R, Wang Y, Zou F, Silverman LM, Drumm ML, Wright FA, Lange EM, Durie PR, Knowles MR, Gene Modifier Study Group
      Genetic modifiers of liver disease in cystic fibrosis.
      19738092 JAMA : the journal of the American Medical Association, 2009 Sep 9 : 302(10)1076-83 PMCID:PMC3711243
    • Treggiari MM, Rosenfeld M, Mayer-Hamblett N, Retsch-Bogart G, Gibson RL, Williams J, Emerson J, Kronmal RA, Ramsey BW, EPIC Study Group
      Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'.
      19470318 Contemporary clinical trials, 2009 May : 30(3)256-68 PMCID:PMC2783320
    • Retsch-Bogart GZ, Quittner AL, Gibson RL, Oermann CM, McCoy KS, Montgomery AB, Cooper PJ
      Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis.
      19420195 Chest, 2009 May : 135(5)1223-32 PMCID:PMC2818415
    • Sagel SD, Gibson RL, Emerson J, McNamara S, Burns JL, Wagener JS, Ramsey BW, Inhaled Tobramycin in Young Children Study Group, Cystic Fibrosis Foundation Therapeutics Development Network
      Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis.
      18822427 The Journal of pediatrics, 2009 Feb. : 154(2)183-8 PMCID:PMC2654617
    • Moskowitz SM, Chmiel JF, Sternen DL, Cheng E, Gibson RL, Marshall SG, Cutting GR
      Clinical practice and genetic counseling for cystic fibrosis and CFTR-related disorders.
      19092437 Genetics in medicine : official journal of the American College of Medical Genetics, 2008 Dec. : 10(12)851-68 PMCID:PMC2810953
    • McCoy KS, Quittner AL, Oermann CM, Gibson RL, Retsch-Bogart GZ, Montgomery AB
      Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis.
      18658109 American journal of respiratory and critical care medicine, 2008 Nov 1 : 178(9)921-8 PMCID:PMC2577727
    • Retsch-Bogart GZ, Burns JL, Otto KL, Liou TG, McCoy K, Oermann C, Gibson RL, AZLI Phase II Study Group
      A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection.
      18041081 Pediatric pulmonology, 2008 Jan. : 43(1)47-58
    • Treggiari MM, Rosenfeld M, Retsch-Bogart G, Gibson R, Ramsey B
      Approach to eradication of initial Pseudomonas aeruginosa infection in children with cystic fibrosis.
      17647287 Pediatric pulmonology, 2007 Sept. : 42(9)751-6
    • Treggiari MM, Rosenfeld M, Retsch-Bogart G, Gibson R, Ramsey B
      Approach to eradication of initial Pseudomonas aeruginosa infection in children with cystic fibrosis.
      17647287 Pediatric pulmonology, 2007 Sept. : 751-6
    • Clancy JP, Rowe SM, Bebok Z, Aitken ML, Gibson R, Zeitlin P, Berclaz P, Moss R, Knowles MR, Oster RA, Mayer-Hamblett N, Ramsey B
      No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutations.
      17347447 American journal of respiratory cell and molecular biology, 2007 July : 37(1)57-66 PMCID:PMC1899350
    • Clancy JP, Rowe SM, Bebok Z, Aitken ML, Gibson R, Zeitlin P, Berclaz P, Moss R, Knowles MR, Oster RA, Mayer-Hamblett N, Ramsey B
      No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutations.
      17347447 American journal of respiratory cell and molecular biology, 2007 July : 57-66
    • Kulich M, Rosenfeld M, Campbell J, Kronmal R, Gibson RL, Goss CH, Ramsey B
      Disease-specific reference equations for lung function in patients with cystic fibrosis.
      15976373 American journal of respiratory and critical care medicine, 2005 Oct 1 : 172(7)885-91
    • Kulich M, Rosenfeld M, Campbell J, Kronmal R, Gibson RL, Goss CH, Ramsey B
      Disease-specific reference equations for lung function in patients with cystic fibrosis.
      15976373 American journal of respiratory and critical care medicine, 2005 Oct 1 : 885-91
    • Deterding R, Retsch-Bogart G, Milgram L, Gibson R, Daines C, Zeitlin PL, Milla C, Marshall B, Lavange L, Engels J, Mathews D, Gorden J, Schaberg A, Williams J, Ramsey B
      Safety and tolerability of denufosol tetrasodium inhalation solution, a novel P2Y2 receptor agonist: results of a phase 1/phase 2 multicenter study in mild to moderate cystic fibrosis.
      15704203 Pediatric pulmonology, 2005 April : 339-48

  • Presentations

    Presentation Title Event Location Date
    Comparison of exome variants from phenotype extremes to a large population-based sample identifies CAV2 and TMC6 as interacting modifiers of chronic Pseudomonas infection in cystic fibrosis North American Cystic Fibrosis Conference Salt Lake City, Utah 2013

Overview

Board Certification(s)

Pediatrics
Pediatric Pulmonology

Medical/Professional School

Washington University School of Medicine, Saint Louis, MO

Residency

University of Washington School of Medicine, Seattle, WA

Fellowship

University of Washington School of Medicine, Seattle, WA

Research Focus Area

Cystic Fibrosis